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1078–5884/00Endovascular Management of Isolated Infrarenal Aortic
Occlusive Disease is Safe and Effective in Selected Patients
S.R. Vallabhaneni,* K. Bjo¨rses, M. Malina, N.V. Dias, B. Sonesson and K. IvancevEndovascular Centre, Malmo¨ University Hospital, 205 02 Malmo¨, SwedenObjective. To examine the safety and efficacy of endovascular management of isolated infrarenal aortic occlusive disease
within our centre.
Design and methods. Retrospective analysis of all patients who underwent endovascular treatment of occlusive disease
that is confined to the infrarenal aorta between September 1993 and November 2004.
Results. Primary aortic stenting was carried out in 16 women and five men using self-expanding (12 patients) and balloon
expanding stents to treat both occlusions (six) and stenoses (15). Indications included intermittent claudication (13), critical
limb ischaemia (six), and distal embolisation (three). Significant postoperative complications within 30 days were noted in
three, including one death. Fifteen patients completed 1-year follow-up with primary patency in 14 and secondary patency in
the remaining patient. Clinical improvement was documented in all patients.
Conclusion. Primary stenting for occlusive disease isolated in the infrarenal aorta is relatively safe in selected patients with
encouraging early follow-up results.Keywords: Angioplasty; Stent; Stent-graft; Aorta; Endovascular management; Complications; Occlusive disease;
Atherosclerosis.Introduction
Endovascular techniques are not widely used to treat
occlusive disease of the infrarenal aorta despite their
popularity in other arterial segments. This is because
occlusive disease isolated in the aorta is not as
common and also due to a perception that endolum-
inal manipulation of a severely diseased aorta could be
hazardous. Conventional surgical solutions are dur-
able but associated with significant perioperative
mortality and morbidity.1,2 The aim of this study was
to examine the safety and efficacy of endovascular
management of isolated infrarenal aortic occlusive
disease.ng author. S.R. Vallabhaneni, MD, FRCS, EBSQ-Vasc,
Centre, Entrance 44, Malmo¨ University Hospital, 205
eden.
: fempop@liv.ac.uk
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All patients who underwent endovascular treatment
of occlusive disease confined to the infrarenal aorta
within one centre between September 1993 and
November 2004 were identified from a prospectively
completed electronic database and their case notes
were analysed retrospectively. Patients who under-
went simultaneous endovascular treatment of the
infrarenal aorta and iliac segments were not included
in this analysis. It has been our usual practice not to
attempt endovascular treatment when the aortic
occlusion extended to within 1 cm of the origin of
the lower main renal artery (juxtarenal occlusions).Technique of intervention
Bilateral common femoral access was established
followed by the administration of heparin. The lesion
is then crossed using hydrophilic guidewires, which
are then exchanged for stiffer wires. AppropriatelyEur J Vasc Endovasc Surg 30, 307–310 (2005)
doi:10.1016/j.ejvs.2005.04.043, available online at http://www.sciencedirect.com onved.
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the stiff guidewires. Self-expanding stents of up to
14 mm diameter can be delivered through 6 F sheaths
(e.g. Luminexx stent, Bard Peripheral Vascular Inc.,
Tempe, AZ, USA) and premounted balloon expand-
able stents of up to 9 mm can be delivered through 7 F
sheaths (e.g. Advanta stent-graft, Atrium Medical
Corp., Hudson, NH, USA). The stent or stents are
then positioned, sheaths are withdrawn and the stents
are deployed. It is standard practice to use the ‘kissing
balloons’ technique and recreate the aortic bifurcation
when dealing with the distal aortic segment. Occasion-
ally, additional trans-brachial access is used for
accurate reference imaging and to pass the initial
guidewires in the antegrade direction. The later lowers
the risk of creating a cephalad-extending dissection of
the aorta. The procedure is usually undertaken under
local anaesthesia with cardio-respiratory monitoring
throughout. Attention is paid to antiplatelet therapy
and the identification and modification of risk factors
(Fig. 1).ResultsPatient details
Seventeen elective and four emergency procedures
were undertaken under local anaesthesia. The 16
(75%) female patients were significantly younger
(mean age 58 years, range 32–89) than the men
(mean 70, range 61–86). (Fisher’s exact, doublesided
pZ0.04). American Society of Anaesthesiologists
(ASA) risk grading was grade 1 in six patients, grade
2 in eight, grade 3 in five and was not documented
in two patients. Five patients, all females, were
documented to have activated protein C (APC)
resistance.
Indications for treatment were disabling claudica-
tion in 13 (62%), critical limb ischaemia in four, critical
ischaemia with distal embolisation in two and distal
embolisation alone in one patient. Another patient had
an acute occlusion of an aortobifemoral bypass graft
cleared by thrombolysis, thereby revealing a severe
stenosis at the aortic anastomosis. All lesions were
atherosclerotic in aetiology. The aorta was occluded in
six patients, nearly occluded in one and stenosed in
the remaining 14. Infrainguinal arteries were free from
significant occlusive disease in 13 patients. Occlusion
of the femoropopliteal segment was noted on both
sides in one patient and on one side only in six.Eur J Vasc Endovasc Surg Vol 30, September 2005Procedural success and safety
Stents were inserted primarily in all patients. Both self-
expanding (12 patients) and balloon expandable stents
of different makes including Memotherm (Angiomed,
Karlsruhe, Germany), Palmaz (Johnson&Johnson,
Warren, NJ, USA), Wallstent (Schneider, Bulach,
Switzerland) and Jostent (Jomed International, Hel-
singborg, Sweden) were used according to the
preference of the physician performing the procedure.
It has been our usual practice to prefer self-expanding
stents in non-calcified lesions and balloon-expandable
stents in heavily calcified or tight lesions. Nominal
diameters of the stents used ranged from 12 to 16 mm
(median 12) and these were dilated using balloons
of nominal diameters ranging from 9 to 16 mm
(median 10).
Postoperative complications were noted in three
patients. One developed a groin haematoma (con-
servatively treated) and another developed a pseu-
doaneurysm (requiring surgical repair). There was one
death within 30 days. This was of a patient with a life-
threatening acute aortic occlusion and deep venous
thrombosis in the presence of untreated and dissemi-
nated pulmonary malignancy. An attempt to treat this
condition was considered justified by the clinical team.
Intra-arterial thrombolysis, aortic recanalisation and
stenting were performed with apparent success
initially. However, the stent occluded within a week
followed by unsuccessful surgical thrombectomy and
death.Follow-up
Standard follow-up was clinical examination and
duplex sonography at 1 month and at 1 year.
Additional follow-up was provided when there were
ongoing problems.One month
At 1 month, duplex sonography confirmed stent
patency in all the 20 patients. All patients reported
improvement in walking distance except one, who
reported little change. This was an 89-year-old in
whom a pressure gradient of 25 mmHg across the
aortic stenosis was abolished by the procedure,
with healing of her foot ulcer occurring. Resting
ankle-brachial pressure index (ABPI) before and
after the procedure was recorded in 16 patients.
The median value of ABPI before treatment was 0.5
(range 0–0.8), which increased to 0.9 (0.5–1.1) after
treatment.
Fig. 1. (A) Digital subtraction angiography via a transbra-
chial catheter showing a short occlusion of the infra-renal
aorta. Run-off appears white due to late filling by contrast
material. (B) Final image after primary deployment of a
Luminexxw stent that has been incrementally dilated from 10
to 14 mm.
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One patient died within the 1st year from cardiac
disease with a patent stent. Three patients underwent
the procedure within the last year and remain
asymptomatic. Of the remaining 16 patients, primary
patency at 1 year was confirmed by duplex sonogra-
phy in 15. The remaining patient required an
endovascular reintervention at 3 months upon occlu-
sion of the aortic stent and was thereafter secondarily
patent at 1 year.
Follow-up beyond 1 year
Seven patients were followed-up beyond the 1st year.
Three patients simply preferred to return to the clinic.
Their ABPIs remained unchanged at 18, 24 and 48
months compared to the postoperative values. The
patient who required secondary intervention pre-
sented 2 years later with occlusion treated by an
aortobifemoral bypass. The aortic stent was confirmed
to be patent on angiography in the other three patients
during different interventions.Discussion
Selection of patients for endovascular surgery of aortic
occlusive disease is influenced by what is perceived to
be an acceptable procedural risk. It is the usual
practice in our unit to offer endovascular surgery to
all patients requiring an intervention, with the excep-
tion of juxtarenal occlusions. During the study period
(11 years), a total of 1265 endovascular interventions
were undertaken for aorto-iliac occlusive disease,
compared to an estimated total of 30 primary
conventional operations. The number of patients in
this study was small due to the lower incidence of
occlusive disease that is confined to the infrarenal
aortic segment. The demographic data of our patients
was unremarkable for this condition. Early and 1-year
follow-up data in this study was encouraging with
clinical improvement in all patients and high rates of
patency.
Due to the retrospective design of this study we
have no data on the patients who were not offered
endovascular treatment or pressure gradients across
the stenoses. Aortic angioplasty is not widely adopted
due to the potential for aortic rupture. Preoperative CT
was performed in nearly half of our patients to
examine calcification within the target segment. A
calcified aorta (particularly circumferential calicifica-
tion) is believed to have a higher potential to rupture
upon balloon dilatation. In Malmo¨, it is considered
best to use smaller-diameter stents in such circum-
stances. Recanalising even to a small calibre (however,Eur J Vasc Endovasc Surg Vol 30, September 2005
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improvement. It is worth noting that aortic rupture has
been reported to complicate aortic angioplasty only
rarely. d’Othee et al. reviewed 606 interventions that
took place over 20 years and found only one aortic
rupture.3 Nevertheless, a range of stent-grafts and
other equipment necessary for the management of
rupture are made available for every aortic interven-
tion in our practice and such preparation is considered
mandatory.
Manipulation within diseased aorta also carries a
risk of creating a dissection and of distal embolisation
with serious consequences. Necessary precautions
include adequate dosage of heparin (target activated
clotting time of 250–300 s) and meticulous caution
with wires and catheters. It is perceived by many,
including the Malmo¨ group, that primary stenting
reduces the risk of both these complications.
Alternative intervention for these patients would be
conventional surgery, mainly in the form of aortobife-
moral or extra-anatomic bypass. The former delivers
durable results, but is associated with significant
perioperative mortality and morbidity in the majority
of centres. The potential for graft infection is a
drawback of extranatomic bypass, particularly in the
recent years with methicillin-resistant Staphylococcus
aureus. Endovascular treatment delivers haemodyna-
mically acceptable results that are likely better than
those of extra-anatomic bypass. There is little doubt
that recovery and mobilisation occur much sooner
after endovascular procedures with a potential for
lower morbidity, mortality and costs.
Over the years, a number of reports of endovascular
treatment of occlusive disease of the infrarenal aorta
have been published and the majority claim immedi-
ate technical success rates of a 100% and low
complication rates.4–8 From the literature and our
experience, it appears safe to combine this technique
with intra-arterial thrombolysis when dealing with
acute situations with a thrombotic component.3
Durability results have also been encouraging.
d’Othee et al. (35 patients) reported 85% primary
patency at 3 years; de Vries et al. (69 patients) reported
primary and secondary patency of 75 and 97%,
respectively, at 5 years; and Feugier et al. (86 patients)
reported primary patency rates of 89 and 77% at 3 and
5 years, respectively.3,9,10
Recognition that occlusive disease of the infrarenal
aorta can be safely treated by endovascular surgery isEur J Vasc Endovasc Surg Vol 30, September 2005essential for the promotion of this technique. Prospec-
tive studies are required to compare endovascular
techniques with the conventional surgical alternatives
in terms of safety, efficacy, durability and economy.
Our experience demonstrates that endovascular man-
agement of infra-renal aortic occlusive disease is safe
and effective.Acknowledgements
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